Roche Eyes Liquid Biopsy As A Boost To Drug Development, Cancer Monitoring
This article was originally published in The Gray Sheet
The Gray Sheet spoke to Roche Molecular Diagnostic's top researcher, Walter Koch, about the promise of liquid biopsy soon after FDA approved its first liquid-biopsy companion diagnostic, Roche's cobas test for the cancer drug Tarceva.
You may also be interested in...
Liquid Biopsy, Particle-Beam Radiotherapy Get 'Moonshot' Commitments
The White House announced 36 new project commitments under its ongoing Cancer Moonshot oncology initiative, including an ambitious project to create an open liquid-biopsy database and a NASA-NCI collaboration to explore the benefits of particle-beam radiotherapy.
US Policy-Makers Prioritize Liquid Biopsies
Liquid biopsies have been a priority topic for policy development by US FDA and the broader Obama administration. During the past year, FDA has kicked itself into high gear to provide test-makers with more insight into its thinking and, this summer, the agency approved the first liquid biopsy test.
Guardant Looking Ahead To Insurers, FDA On Liquid Biopsy
Guardant Health recently announced that the first US health insurance plan covered its Guardant360 liquid biopsy system. CEO Helmy Eltoukhy spoke to Medtech Insight about the milestone and the firm's plans to gain FDA approval as the agency moves to oversee laboratory-developed tests. Read the story and listen to the podcast interview.